Abstract
The natural progression of primary biliary cirrhosis (PBC) has been modeled by a number of investigators based on Cox’s proportional hazards analysis1–3. The utility of these models is largely two-fold. On the one hand, these models have been used as a clinical tool in assessing prognosis with or without treatment. For example, the natural history model for PBC has been used in determining prognosis following transplantation, thereby assisting transplant physicians and surgeons in their decisions about patient selection and timing of transplantation4. On the other hand, these models are useful from the standpoint of clinical research. For instance, the prognostic indices of the models may be used as parameters of disease severity in risk stratification in clinical trials evaluating new treatment modalities5.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989:10:1–7.
Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptotic and symptomatic primary biliary cirrhosis. N Engl J Med 1983;308:1–7.
Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final result of an international trial. Gastroenterology 1985;89:1084–91.
Wiesner RH, Porayko MK, Dickson ER, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992;16:1290–9.
Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284–90.
Grambsch PM, Dickson ER, Kaplan M, LeSage G, Fleming TR, Langworthy AL. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989;10:846–50.
Robert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996;24:1392–4.
Grambsch PM, Dickson ER, Wiesner RH, Langworthy A. Application of the Mayo primary biliary cirrhosis survival model to Mayo liver transplant patients. Mayo Clin Proc 1989;64:699–704.
Kim WR, Wiesner RH, Therneau TM, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology (In press).
Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342–7.
Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996;110:1515–19.
Heathcote EJ, Lindor KD, Poupon R, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884–90.
Kilmurry MR, Heathcote EJ, Cauch-Dudek K, et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996;23:1148–53.
Lindor KD, Therneau TM, Hermans JE, Dickson ER. Mayo risk score accurately predicts patient outcome with ursodeoxycholic acid treatment of primary biliary cirrhosis [abstract]. Hepatology 1996;24:167A.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Kim, W.R., Dickson, E.R. (1998). Natural history models of primary biliary cirrhosis. In: Lindor, K.D., Heathcote, E.J., Poupon, R. (eds) Primary Biliary Cirrhosis. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4884-9_9
Download citation
DOI: https://doi.org/10.1007/978-94-011-4884-9_9
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6047-9
Online ISBN: 978-94-011-4884-9
eBook Packages: Springer Book Archive